메뉴 건너뛰기




Volumn 39, Issue 12, 2011, Pages 1117-1118

Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; EPIRUBICIN; MESSENGER RNA; PROTEASOME; PROTEASOME BETA5 SUBUNIT; THALIDOMIDE; UNCLASSIFIED DRUG;

EID: 81155134744     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.09.003     Document Type: Letter
Times cited : (24)

References (10)
  • 1
    • 0035300479 scopus 로고    scopus 로고
    • The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
    • Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
    • (2001) Cancer Res , vol.61 , pp. 3071-3076
    • Hideshima, T.1    Richardson, P.2    Chauhan, D.3
  • 2
    • 20444433230 scopus 로고    scopus 로고
    • Bortezomib or high dose dexamethazone for relapsed multiple myeloma
    • Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high dose dexamethazone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
    • (2005) N Engl J Med , vol.352 , pp. 2487-2498
    • Richardson, P.G.1    Sonneveld, P.2    Schuster, M.W.3
  • 3
    • 77649092410 scopus 로고    scopus 로고
    • Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma
    • Jakubowiak A.J., Kendall T., Al-Zoubi A., et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009, 27:5015-5022.
    • (2009) J Clin Oncol , vol.27 , pp. 5015-5022
    • Jakubowiak, A.J.1    Kendall, T.2    Al-Zoubi, A.3
  • 4
    • 33846688196 scopus 로고    scopus 로고
    • Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors
    • Cheriyath V., Jacobs B.S., Hussein M.A. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors. Drugs R D 2007, 8:1-12.
    • (2007) Drugs R D , vol.8 , pp. 1-12
    • Cheriyath, V.1    Jacobs, B.S.2    Hussein, M.A.3
  • 5
    • 47949089799 scopus 로고    scopus 로고
    • Point mutation of the PSMB5 gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line
    • Lü S., Yang J., Song X., et al. Point mutation of the PSMB5 gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther 2008, 326:423-431.
    • (2008) J Pharmacol Exp Ther , vol.326 , pp. 423-431
    • Lü, S.1    Yang, J.2    Song, X.3
  • 6
    • 67049107847 scopus 로고    scopus 로고
    • Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line
    • Lü S., Yang J., Chen Z., et al. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Exp Hematol 2009, 37:831-837.
    • (2009) Exp Hematol , vol.37 , pp. 831-837
    • Lü, S.1    Yang, J.2    Chen, Z.3
  • 7
    • 52049086674 scopus 로고    scopus 로고
    • Overexpression of the PSMB5 gene contributes to bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from Jurkat line
    • Lü S., Chen Z., Yang J., et al. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp Hematol 2008, 36:1278-1284.
    • (2008) Exp Hematol , vol.36 , pp. 1278-1284
    • Lü, S.1    Chen, Z.2    Yang, J.3
  • 8
    • 53049106912 scopus 로고    scopus 로고
    • Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein
    • Oerlemans R., Franke N.E., Assaraf Y.G., et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008, 112:2489-2499.
    • (2008) Blood , vol.112 , pp. 2489-2499
    • Oerlemans, R.1    Franke, N.E.2    Assaraf, Y.G.3
  • 9
    • 77955712506 scopus 로고    scopus 로고
    • Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
    • Ri M., Iida S., Nakashima T., et al. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 2010, 24:1506-1512.
    • (2010) Leukemia , vol.24 , pp. 1506-1512
    • Ri, M.1    Iida, S.2    Nakashima, T.3
  • 10
    • 77954368003 scopus 로고    scopus 로고
    • G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation
    • Yang Y.M., Lee S., Nam C.W., et al. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation. Carcinogenesis 2010, 31:1230-1237.
    • (2010) Carcinogenesis , vol.31 , pp. 1230-1237
    • Yang, Y.M.1    Lee, S.2    Nam, C.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.